Travere Therapeutics (NASDAQ:TVTX) · earnings miss
Quarter
Q3
EPS estimate to actual
$0.28→ to -$0.31
Revenue estimate to actual
$194.7M→ to $224.6M
At a glance
Key takeaways
01Travere Therapeutics missed EPS expectations by $0.59 per share, reporting -$0.31 actual versus $0.28 consensus estimate in Q3 2026.
02Revenue of $224.6M exceeded analyst estimates of $194.7M, showing strong top-line performance despite earnings miss.
03The company has reported negative EPS for two consecutive quarters, with Q2 at -$0.10 and Q3 at -$0.31.
04Stock trades at $49.41 with $3.1B market capitalization as investors reassess growth assumptions following the significant earnings shortfall.
Earnings Results
Travere Therapeutics (NASDAQ:TVTX) reported quarterly earnings results on November 02, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.31, missing the consensus estimate of $0.28 by $0.59 per share. Revenue came in at $224.6M, beating the estimate of $194.7M.
Company Overview
Travere Therapeutics's stock moved following the earnings release. The stock currently trades at $49.41 with a market capitalization of $3.1B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 211% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Travere Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.